Research Paper Volume 15, Issue 11 pp 5066—5074
Efficacy of first-line tyrosine kinase inhibitor between unresectable stage III and stage IV EGFR-mutated non-small cell lung cancer patients
Figure 1. Frequency of initial treatment modalities for EGFR-mutated non-small cell lung cancer patients. (A) stage III. (B) stage IV. EGFR: Epidermal growth factor receptor. TKI: tyrosine kinase inhibitor.